Side-by-side financials for CABA and AMGN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CABA | AMGN |
|---|---|---|
| Market cap | - | $190.92 B |
| US-listed rank | - | #79 |
| Revenue (latest FY) | - | $36.75B |
| Net income (latest FY) | -$167.86M | $7.71B |
| Net margin | - | 21.0% |
| P/E (trailing FY) | - | 24.8 |
| SEC filings | 423 | 1,011 |
Full pages: Cabaletta Bio, Inc. and AMGEN INC, or browse the full rankings.